A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Clinical trial NCT06524375 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06524375
- Sponsor
- Genentech, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-09
- Primary completion
- 2026-10-31
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.